financetom
Business
financetom
/
Business
/
Acadia Q2 revenue beats estimates 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Acadia Q2 revenue beats estimates 
Jul 29, 2025 1:48 PM

Overview

* Acadia Q2 revenue beats analyst expectations, per LSEG data

* NAREIT FFO per share rises 8% yr/yr, indicating improved operational performance

* Co completed $157 mln in street retail acquisitions, expanding NYC portfolio

Outlook

* Acadia reaffirms full-year Core Same Property NOI growth of 5-6%

* Company revises 2025 net earnings guidance to $0.09-$0.13 per share

Result Drivers

* SAME-PROPERTY NOI - Achieved 4.2% growth driven by increased occupancy

* LEASE EXECUTION - Signed 35,000 sq ft lease with LA Fitness in San Francisco

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $100.59 $89.90

Revenue mln mln (3

Analysts

)

Q2 EPS $0.01

Q2 Net -$20.94

Income mln

Q2 Basic $0.01

EPS

Q2 FFO $0.27

Per

Share

Q2 $760,000

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the commercial reits peer group is "buy"

* Wall Street's median 12-month price target for Acadia Realty Trust ( AKR ) is $23.00, about 19.1% above its July 28 closing price of $18.60

* The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 53 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM
AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM
Apr 11, 2024
(Reuters) -AstraZeneca said on Thursday it intends to increase annual dividend for 2024 by 7% to $3.10 per share, betting on strong performance and cash generation on the back of its blockbuster drugs and several recent acquisitions. The announcement comes ahead of its annual general meeting later in the day, where investors are preparing to vote on a policy that...
Lufthansa extends flight cancellations from Frankfurt to Tehran on security concerns
Lufthansa extends flight cancellations from Frankfurt to Tehran on security concerns
Apr 11, 2024
FRANKFURT, April 11 (Reuters) - German airline Lufthansa has extended the cancellation of daily flights from Frankfurt to Tehran due to security concerns until April 13, a spokesperson said on Thursday. The decision was taken last weekend to avoid a situation where the airline's crew had to stay overnight in Tehran, the spokesperson added. ...
PRESS DIGEST- Wall Street Journal - April 11
PRESS DIGEST- Wall Street Journal - April 11
Apr 10, 2024
April 11 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Vertex Pharmaceuticals ( VRTX ) has agreed to acquire Alpine Immune Sciences ( ALPN ) for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue...
Gerresheimer expects sales boost from burgeoning obesity drugs sector
Gerresheimer expects sales boost from burgeoning obesity drugs sector
Apr 11, 2024
April 11 (Reuters) - German packaging and medical equipment maker Gerresheimer expects diabetes and diet drugs to contribute 350 million euros ($376 million) of annual revenue by the 2026/27 financial year, CFO Bernd Metzner told Reuters after the company reported first-quarter results on Thursday. Obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's ( LLY ) Zepbound are administered...
Copyright 2023-2026 - www.financetom.com All Rights Reserved